MAPT and Alzheimer disease: Similarly, after the use of the NLRP3 inflammasome inhibitor MCC950, the clearance of Aβ in APP/PS1 transgenic mice was significantly increased, and the tau pathology was significantly reduced, indicating again that the NLRP3 inflammasome plays an important role in AD (Swanson et al., 2019).